Canadian cardiovascular society atrial fibrillation guidelines 2010: Etiology and initial investigations

Canadian Journal of Cardiology

Volumn 27, Issue 1, 2011, Pages 31-37

  Healey, Jeff S ^a   Parkash, Ratika ^b   Pollak, Tim ^c   Tsang, Teresa ^d   Dorian, Paul ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DABIGATRAN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COMORBIDITY; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL HISTORY; PATHOGENESIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; QUALITY OF LIFE; STROKE; THROMBOEMBOLISM; CANADA; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; MEDICAL SOCIETY; PATIENT CARE PLANNING; RISK FACTOR;

ATRIAL FIBRILLATION; CANADA; COMORBIDITY; HUMANS; PATIENT CARE PLANNING; QUALITY OF LIFE; RISK FACTORS; SOCIETIES, MEDICAL; THROMBOEMBOLISM;

EID: 79953313037     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.11.015     Document Type: Article

References (45)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006;48: 854-906.
2. Dorian P, Guerra PG, Kerr CR, et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophsiol 2009;2:213-4.
3. Chen PS, Pressley JC, Tang AS, et al. New observations on atrial fibrillation before and after surgical treatment in patients with the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1992;19:974-81.
4. Haissaguerre M, Fischer B, Labbe T, et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992;69:493-7.
5. Paquette M, Roy D, Talajic MM, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000;86:764-8.
6. Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electro-physiol 2006;19:762-8.
7. Kannel WB, Wolf PA, Benjamin EJ. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
8. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
9. Kannell WB, Abbot RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982; 306:1018-22.
10. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978;28:973-7.
11. Krahn AD. The natural history of atrial fibrillation: incidence, risk factors and prognosisin the Manitoba Follow-up Study. Am J Med 1995;98:476-84.
12. Verdecchia P, Reboldi GP, Gattobigio R, et al. Atrial fibrillation in hypertension. Hypertension 2003;41:218-23.
13. Healey JS, Connolly SJ. Atrial Fibrillation: hypertension as a causative agent, risk factor for complications and potential therapeutic target. Am Heart J 2003;91:9G-14G.
14. Krahn AD, Klein GJ, Kerr C, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med 1996;156:2221-4.
15. Sharma AD, Klein GJ, Guiradon GM, et al. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation 1985;72:161-9.
16. Skanes AC, Krahn AD, Yee R, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial of Physiologic Pacing. J Am Coll Cardiol 2001;38:167-72.
17. Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007;357: 1000-8.
18. Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrialbased pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation 2006;114:11-7.
19. Sweeny MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107:2932-7.
20. Ntep-Gweth M, Zimmermann M, Meiltz A, et al. Atrial fibrillation in Africa: clinical characteristics, prognosis and adherence to guidelines in Cameroon. Europace 2010;12:482-7.
21. Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003;107:2589-94.
22. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
23. Conen D, Tedrow UB, Cook NR, et al. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008;300:2489-96.
24. Heuzey JY, Breithardt G, Camm AJ, et al. The RECORDAF study: design, baseline data and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010;105:687-93.
25. Molina L, Mont L, Marrugat J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace 2008;10:618-23.
26. Hackman DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2010;26:249-58.
27. Quinn RR, Hemmelgarn BR, Padwal RS, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2010;26:241-8.
28. Kim DD, Young S, Cutfield R, et al. A survey of thyroid function test abnormalities in patients presenting with atrial fibrillation and atrial flutter to a New Zealand district hospital. N Z Med J 2008;121:82-6.
29. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-57.
30. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
31. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987;147:1561-4.
32. Hart RG, Halperin JL. Atrial fibrillation and stroke. Revisiting the dilemmas. Stroke 1994;25:1337-41.
33. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin: predictive ability of risk stratification schemes for primary and secondary prevention. Thrombo Haemost 2009;101:367-72.
34. Hart RG, Pearce LA, Aquilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
35. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;30:2066-78.
36. Hart RG. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
37. Hughes M, Lip GYH. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost-effectiveness data. Thrombo Haemost 2009;99:295-304.
38. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-10.
39. Connolly SJ, Pogue J,Eikelboom J,et al. Benefit oforal anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
40. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74-90.
41. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008;39:1482-6.
42. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
43. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35: 183-7.
44. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
45. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 2008 Jul;29(13):1618-24. Epub 2008 May 31.